Citrafleet

Citrafleet is an oral bowel‑cleansing preparation that combines sodium picosulfate, magnesium oxide and citric acid. The product is supplied in a liquid formulation intended for use in the European Union market. It works as a stimulant laxative together with an osmotic component to promote evacuation of the colon before diagnostic procedures. Citrafleet does not contain a specified strength in the publicly available data, currently listed.

Citrafleet is indicated for bowel preparation in adults who require a clean colon for diagnostic or therapeutic procedures.

- Colonoscopy preparation - Barium enema or other radiologic colon imaging - Pre‑operative bowel cleansing before colorectal surgery - Situations where rapid and thorough colonic evacuation is desired - Use in clinical trials requiring standardized bowel cleansing

The most frequently reported adverse events with Citrafleet are related to its laxative action and electrolyte changes.

Common: - Abdominal cramping or discomfort - Diarrhea or loose stools - Nausea - Thirst or mild dehydration - Bloating - Transient electrolyte imbalance (e.g., mild hypokalemia)

Serious: - Severe dehydration - Electrolyte disturbances requiring medical attention (e.g., significant hyponatremia) - Persistent vomiting - Acute renal impairment - Allergic reactions such as rash or angioedema

Before using Citrafleet, healthcare providers should evaluate patient-specific factors and advise on appropriate preparation to minimize risks.

- Assess renal function and electrolyte status - Avoid use in patients with known bowel obstruction or perforation - Use with caution in individuals with inflammatory bowel disease - Review medication history for drugs that affect fluid balance - Ensure adequate fluid intake during the regimen - Consider alternative preparations in pregnancy or lactation when safety is uncertain - Provide clear instructions on timing and diet

Citrafleet may interact with other medicines that influence fluid, electrolyte balance or gastrointestinal motility.

Avoid: - Concomitant use of other potent laxatives or stool softeners - High‑dose anticholinergic agents that reduce bowel motility - Loop or thiazide diuretics that may exacerbate electrolyte loss

Use with caution: - ACE inhibitors or ARBs due to risk of hyperkalemia - NSAIDs that can affect renal function - Oral potassium supplements - Certain antibiotics (e.g., quinolones) whose absorption may be reduced